Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (MOIO)
Randomized Phase III Trial of Standard Immunotherapy (IO) by Checkpoint Inhibitors, Versus Reduced Dose Intensity of IO in Patients With Locally Advanced or Metastatic Cancer in Response After 6 Months of Standard IO
Sponsor: UNICANCER
A PHASE3 clinical study on Basal Cell Carcinoma and Cervical Cancer, this trial is actively recruiting participants. The trial is conducted by UNICANCER and has accumulated 9 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE3
-
Oct 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Jul 2022 — Sep 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jul 2022 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE3
-
Nov 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Angers, France , Avignon, France , Bayonne, France , Besançon, France , Bordeaux, France , Boulogne-sur-Mer, France , Caen, France , Clermont-Ferrand, France , Créteil, France , Dijon, France and 23 more locations